Schering's Specialty Focus Includes Alzheimer's, Oncology
This article was originally published in Pharmaceutical Approvals Monthly
Schering-Plough's specialty drug pipeline - part of big pharma's overall efforts to hedge against the dwindling primary care market - includes several potential first-in-class or best-in-class compounds addressing oncology, Alzheimer's disease, Parkinson's disease and other specialty areas
You may also be interested in...
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.